Synthesis, characterization and osteoconductivity properties of bone fillers based on alendronate-loaded poly(ε-caprolactone)/hydroxyapatite microspheres

Journal of Materials Science: Materials in Medicine

Volumn 22, Issue 3, 2011, Pages 547-555

  Chen, Jianhong ^a   Luo, Yun ^a   Hong, Liangqing ^a   Ling, You ^b   Pang, Jun ^a   Fang, Youqiang ^a   Wei, Kun ^b   Gao, Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONATE; ALKALINE PHOSPHATASE ACTIVITY; BISPHOSPHONATES; BONE DEFECT; BONE REPAIR; BONE SUBSTITUTES; BONE-FILLERS; CAPROLACTONE; COMPOSITE MICROSPHERES; CONTROLLED RELEASE; DRUG CONTROLLED RELEASE; ENCAPSULATION EFFICIENCY; HUMAN BONES; IN-VITRO; LOCAL THERAPY; MATRIX; MESENCHYMAL STEM CELL; OIL/WATER EMULSION; OSTEOCONDUCTIVITY; OSTEOGENESIS; OSTEOGENIC; OSTEOGENIC DIFFERENTIATION; POLY(E-CAPROLACTONE); SUSTAINED RELEASE;

APATITE; BONE; CELL CULTURE; DEFECTS; EMULSIFICATION; ENCAPSULATION; HYDROXYAPATITE; PHOSPHATASES; STEM CELLS; TISSUE;

MICROSPHERES;

ALENDRONIC ACID; ALKALINE PHOSPHATASE; HYDROXYAPATITE; POLYCAPROLACTONE;

ARTICLE; BONE CONDUCTION; BONE REMODELING; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPOSITE MATERIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; EMULSION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; OSTEOBLAST; PRIORITY JOURNAL; SURFACE PROPERTY; SYNTHESIS;

ALENDRONATE; ALKALINE PHOSPHATASE; BONE AND BONES; BONE SUBSTITUTES; CELL PROLIFERATION; CELL SURVIVAL; DURAPATITE; HUMANS; MESENCHYMAL STEM CELLS; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; OSTEOGENESIS; PARTICLE SIZE; POLYESTERS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 79958131487     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-011-4232-8     Document Type: Article

References (38)

1. Habraken WJ, Wolke JG, Jansen JA. Ceramic composites as matrices and scaffolds for drug delivery in tissue engineering. Adv Drug Deliv Rev. 2007;59:234-48. (Pubitemid 46879968)
2. Dhanaraju MD, Gopinath D, Ahmed MR, Jayakumar R, Vamsadhara C. Characterization of polymeric poly(ε-caprolactone) injectable implant delivery system for the controlled delivery of contraceptive steroids. J Biomed Mater Res A. 2006;76:63-72. (Pubitemid 43075682)
3. Shen H, Hu X, Yang F, Bei J, Wang S. An injectable scaffold: rhBMP-2-loaded poly(lactide-co-glycolide)/hydroxyapatite composite microspheres. Acta Biomater. 2010;6:455-65.
4. Boonsongrit Y, Abe H, Sato K, Naito M, Yoshimura M, Ichikawa H, et al. Controlled release of bovine serum albumin from hydroxyapatite microspheres for protein delivery system. Mater Sci Eng B. 2008;48:162-5. (Pubitemid 351215837)
5. Leach JK, Kaigler D, Wang Z, Krebsbach PH, Mooney DJ. Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration. Biomaterials. 2006;27:3249-55. (Pubitemid 43344337)
6. Link DP, van den Dolder J, van den Beucken JJ, Wolke JG, Mikos AG, Jansen JA. Bone response and mechanical strength of rabbit femoral defects filled with injectable CaP cements containing TGF-β1 loaded gelatin microparticles. Biomaterials. 2008;29:675-82. (Pubitemid 350181047)
7. Huang J, Lin YW, Fu XW, Best SM, Brooks RA, Rushton N, et al. Development of nano-sized hydroxyapatite reinforced composites for tissue engineering scaffolds. J Mater Sci Mater Med. 2007;18:2151-7. (Pubitemid 350167383)
8. Chen F, Lam WM, Lin CJ, Qiu GX, Wu ZH, Luk KD, et al. Biocompatibility of electrophoretical deposition of nanostructured hydroxyapatite coating on roughen titanium surface. In vitro evaluation using mesenchymal stem cells. J Biomed Mater Res B Appl Biomater. 2007;82:183-9.
9. Yunoki S, Ikoma T, Monkawa A, Ohta K, Kikuchi M, Sotome S, et al. Control of pore structure and mechanical property in hydroxyapatite/collagen composite using unidirectional ice growth. Mater Lett. 2006;60:999-1002. (Pubitemid 43088652)
10. Pitt CG. Poly(ε-caprolactone) and its copolymers. In: Chasin M, Langer R, editors. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker; 1990. p. 71-120.
11. Chang HI, Lau YC, Yan C, Coombes AG. Controlled release of an antibiotic, gentamicin sulphate, from gravity spun polycaprolactone fibers. J Biomed Mater Res A. 2008;84:230-7. (Pubitemid 350244264)
12. Oh SH, Lee JY, Ghil SH, Lee SS, Yuk SH, Lee JH. PCL microparticle- dispersed PLGA solution as a potential injectable urethral bulking agent. Biomaterials. 2006;27:1936-44. (Pubitemid 41759488)
13. Sun H, Mei L, Song C, Cui X, Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2006;27:1735-40. (Pubitemid 41759467)
14. Gulley J, Dahut WL. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Urology. 2003;62(Suppl 1):147-54. (Pubitemid 41116574)
15. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-81. (Pubitemid 36886244)
16. Green JR. Antitumor effects of bisphosphonates. Cancer. 2003; 97(Suppl 3):840-7. (Pubitemid 36125821)
17. García-Moreno C, Serrano S, Nacher M, Farré M, Díez A, Mariñoso ML, et al. Effect of alendronate on cultured normal human osteoblasts. Bone. 1998;22:233-9. (Pubitemid 28127478)
18. Benyettou F, Lalatonne Y, Sainte-Catherine O, Monteil M, Motte L. Superparamagnetic nanovector with anti-cancer properties: gamma Fe2O3@Zoledronate. Int J Pharm. 2009;379:324-7.
19. van Beek ER, Löwik CW, Papapoulos SE. Effect of alendronate treatment on the osteoclasto-genic potential of bone marrow cells in mice. Bone. 1997;20:335-40. (Pubitemid 27196656)
20. Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. 2001;29:553-9. (Pubitemid 33124298)
21. Shi X, Wang Y, Ren L, Gong Y, Wang DA. Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications. Pharm Res. 2009;26:422-30.
22. Boanini E, Torricelli P, Gazzano M, Giardino R, Bigi A. Alendronate- hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials. 2008;29:790-6. (Pubitemid 350266051)
23. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617-27.
24. Bigi A, Boanini E, Capuccini C, Fini M, Mihailescu IN, Ristoscu C, et al. Biofunctional alendronate-hydroxyapatite thin films deposited by MatrixAssisted Pulsed Laser Evaporation. Biomaterials. 2009;30:6168-77.
25. Shi X, Wang Y, Varshney RR, Ren L, Zhang F, Wang DA. In vitro osteogenesis of synovium stem cells induced by controlled release of bisphosphate additives from microspherical mesoporous silica composite. Biomaterials. 2009;30:3996-4005.
26. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-36.
27. Ma PX, Choi JW. Biodegradable polymer scaffolds with well-defined interconnected spherical pore network. Tissue Eng. 2001;7:23-33. (Pubitemid 32175959)
28. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials. 2005;26:6941-9. (Pubitemid 41095518)
29. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev. 2000;42:175-95. (Pubitemid 30645777)
30. Guo X, Gough JE, Xiao P, Liu J, Shen Z. Fabrication of nanostructured hydroxyapatite and analysis of human osteoblastic cellular response. J Biomed Mater Res A. 2007;82:1022-32. (Pubitemid 47312918)
31. Kuljanin J, Janković I, Nedeljković J, Prstojević D, MarinkovićV. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions. J Pharm Biomed Anal. 2002;28:1215-20. (Pubitemid 34607407)
32. Choong CS, Hutmacher DW, Triffitt JT. Co-culture of bone marrow fibroblasts and endothelial cells on modified polycaprolactone substrates for enhanced potentials in bone tissue engineering. Tissue Eng. 2006;12(9):2521-31. (Pubitemid 46141275)
33. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282:1-18. (Pubitemid 39178480)
34. Huang W, Wang Y, Ren L, Du C, Shi X. A novel PHBV/HA microsphere releasing system loaded with alendronate. Mater Sci Eng C. 2009;29:2221-5.
35. Serrano MC, Pagani R, Vallet-Regí M, Peña J, Rámila A, Izquierdo I, et al. In vitro biocompatibility assessment of poly(e-caprolactone) films using L929 mouse fibroblasts. Biomaterials. 2004;25:5603-11. (Pubitemid 38680488)
36. Wang DA, Williams CG, Yang F, Cher N, Lee H, Elisseeff JH. Bioresponsive phosphoester hydrogels for bone tissue engineering. Tissue Eng. 2005;11:201-13. (Pubitemid 40515188)
37. Xue W, Krishna BV, Bandyopadhyay A, Bose S. Processing and biocompatibility evaluation of laser processed porous titanium. Acta Biomater. 2007;3:1007-18. (Pubitemid 47382673)
38. Cenni E, Granchi D, Avnet S, Fotia C, Salerno M, Micieli D, et al. Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials. 2008;29:1400-11.